Afya Limited (NASDAQ:AFYA) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Afya Limited (NASDAQ:AFYA) has received a consensus rating of "Hold" from six research firms, with one sell rating, two hold ratings, and three buy ratings.
• UBS Group recently upgraded Afya from "neutral" to "buy," while analysts estimate a 1-year target price for the stock at $18.20.
• The company has a market capitalization of $1.46 billion and its stock was down 0.7%, opening at $15.60 on Monday.

Shares of Afya Limited (NASDAQ:AFYA - Get Free Report) have received a consensus rating of "Hold" from the six research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $18.20.

A number of research firms have recently weighed in on AFYA. UBS Group upgraded shares of Afya from a "neutral" rating to a "buy" rating and cut their price target for the company from $19.50 to $19.00 in a report on Monday, September 8th. Wall Street Zen upgraded shares of Afya from a "buy" rating to a "strong-buy" rating in a report on Saturday. Zacks Research upgraded shares of Afya to a "hold" rating in a report on Friday, August 8th. JPMorgan Chase & Co. upgraded shares of Afya from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $23.50 to $24.50 in a report on Monday, September 8th. Finally, Citigroup upgraded shares of Afya from a "sell" rating to a "neutral" rating and dropped their target price for the stock from $16.00 to $14.00 in a report on Tuesday, July 29th.

Afya Stock Down 0.7%

Afya stock opened at $15.60 on Monday. The company has a market capitalization of $1.46 billion, a P/E ratio of 11.82, a P/E/G ratio of 0.54 and a beta of 0.56. The firm's fifty day simple moving average is $15.06 and its 200-day simple moving average is $16.98. The company has a current ratio of 0.94, a quick ratio of 0.94 and a debt-to-equity ratio of 0.22. Afya has a 1-year low of $13.47 and a 1-year high of $19.90.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AFYA. Northern Trust Corp raised its holdings in Afya by 109.7% in the 4th quarter. Northern Trust Corp now owns 40,054 shares of the company's stock worth $636,000 after acquiring an additional 20,957 shares during the period. Jane Street Group LLC grew its position in Afya by 3.7% in the 4th quarter. Jane Street Group LLC now owns 56,341 shares of the company's stock worth $895,000 after purchasing an additional 2,032 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Afya in the 4th quarter worth $228,000. D. E. Shaw & Co. Inc. grew its position in Afya by 32.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 82,817 shares of the company's stock worth $1,315,000 after purchasing an additional 20,498 shares during the last quarter. Finally, Lazard Asset Management LLC grew its position in Afya by 54.3% in the 4th quarter. Lazard Asset Management LLC now owns 97,313 shares of the company's stock worth $1,545,000 after purchasing an additional 34,246 shares during the last quarter. Institutional investors own 88.02% of the company's stock.

Afya Company Profile

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.